Reasons for stopping drugs are monitored in New ZealandBMJ 1996; 313 doi: http://dx.doi.org/10.1136/bmj.313.7059.756 (Published 21 September 1996) Cite this as: BMJ 1996;313:756
- David M Coulter, Director, intensive medicines monitoring programme
- National Toxicology Group, Dunedin School of Medicine, PO Box 913, Dunedin, New Zealand
EDITOR,—The New Zealand intensive medicines monitoring programme is a system for monitoring adverse events in the early postmarketing period of selected new drugs. Each drug is monitored for four to five years usually, and cohorts of identifiable patients are established from prescription information sent in from virtually all pharmacies throughout the country, with a population base of 3.6 million. The average size of each cohort is 10 228. Each dispensing episode is recorded throughout the monitoring period; the data include date, daily …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial